GoodRx Holdings Inc.

09/24/2024 | Press release | Distributed by Public on 09/24/2024 15:42

Back to School Rush Spurs Demand for Epinephrine Auto Injectors Amid Shortage

Key takeaways:

  • Epinephrine auto-injector fills increased as students prepared to go back to school during the summer.

  • This may worsen existing shortages of the medication.

  • The FDA's recent approval of neffy, a needle-free nasal spray option for anaphylaxis, offers a new alternative for those unable to fill their prescription.

CarrieCaptured/iStock via Getty Images Plus

During this year's back-to-school season, demand for epinephrine (EpiPen, EpiPen Jr, Adrenaclick, Auvi-Q) autoinjectors spiked. And that may intensify existing shortages of the medication.

Epinephrine prescriptions typically peak in August as parents and schools scramble to refill the autoinjector before the new school year begins. In previous years, we've usually seen a nearly 40% increase in fills from July to August. Although this year's increase in fills between July and August was 31%, overall fills for EpiPen were higher compared to previous years.

Meanwhile, several epinephrine auto-injectors were facing a shortage as of August 16, 2024. Both Mylan and Amneal (EpiPen, EpiPen Jr, and epinephrine) were experiencing back orders for auto-injectors and unable to estimate a release date for the back orders.

A supply disruption often leads to a medication shortage. During a shortage, a pharmacy may not be able to fill all or part of a prescription. In this case, patients may need to seek an alternative or wait for availability.

How to navigate this shortage

Here's what to do if you can't fill your epinephrine due to shortages.

  • Talk to your pharmacist. They may be able to direct you to a different pharmacy that has epinephrine. Or they may know when a new shipment will arrive.

  • Speak to your prescriber. They may also be able to help you find a pharmacy with epinephrine or can suggest an alternative. The FDA approved neffy, the first needle-free spray for anaphylaxis, on August 9, 2024. ARS Pharmaceuticals, neffy's manufacturer, expects the spray to be available before October 4. Your prescriber can tell you whether the nasal spray is an option for you.

  • Reach out to your insurance. They may be able to expand coverage for an alternative, such as neffy.

How much do epinephrine autoinjectors cost?

If you're paying out of pocket, the average cash price for a pack of two injectors can range from nearly $300 to over $1,600. The top three most-filled epinephrine auto-injectors are the cheaper, generic ones (see table below).

In general, most Medicare and insurance plans cover epinephrine autoinjectors. But they may restrict the amount they'll cover.

Most patients with commercial insurance can expect to pay $25 for neffy. Those without insurance or those with high out-of-pocket costs may be able to bring down the cash price to $199 for two doses using GoodRx.

Summing it all up

Epinephrine auto-injector fills increased as students got ready to go back to school. The increase in demand may cause some supply chain strain due to an existing shortage. Talk to your prescriber about alternatives if you're having trouble filling your prescription.

Methodology

Using a representative sample of U.S. prescription fills, we calculated the fill rate as the number of fills for epinephrine autoinjectors divided by the number of fills of all drugs, after removing drugs with a seasonality component in prescribing patterns. Prescription fills were reported from retail pharmacies from January 1, 2021 to July 27, 2024.

Epinephrine medications included in analysis: Autoinjectors: epinephrine (EpiPen), epinephrine (Adrenaclick), epinephrine (EpiPen Jr), EpiPen, EpiPen Jr, Auvi-Q.

Why trust our experts?

Written by:
Elsie Yi, MPH
Elsie is a research analyst at GoodRx. Prior to joining GoodRx, Elsie worked as an intern with SCAN Health Plan and with All of Us' UC Irvine research consortium, where she developed her analytical skills.
Edited by:
Tori Marsh, MPH
Tori Marsh is GoodRx's resident expert on prescription drug pricing, prescribing trends, and drug savings. She oversees the GoodRx drug database, ensuring that all drug information is accurate and up to date.
Analysis by:
Sasha Guttentag, PhD
Sasha Guttentag, PhD, is a research scientist at GoodRx.
View All References (1)
expand_more

U.S. Food and Drug Administration. (2024). FDA approves first nasal spray for treatment of anaphylaxis.

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

Was this page helpful?

thumb_up_outlinedthumb_down_outlined
print_outlinedemail_outlined

Let's Help You Breathe Better

Sign up for our GoodRx Health Asthma and Allergies Newsletter to receive up-to-date information on the latest medications, treatments, and savings that are most relevant to you.
Email address
Subscribe
I would also like to sign up for a free GoodRx account

By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.